{
  "docId": "019de072-0f48-75dc-8e26-6c36719c246a",
  "docSlug": "59aa3600901f9a5fdbc1ca4ce261b5cc",
  "documentTitle": "Vigil Neuroscience | IPO Presentation Deck | 54 slides",
  "authorId": "vigil-neuroscience",
  "authorName": "Vigil Neuroscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 30,
  "pageCount": 54,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a combination of longitudinal imaging and scatter/dot plots to establish clinical validity for biomarkers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-0f48-75dc-8e26-6c36719c246a/30",
  "deckHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a",
  "deckJsonHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a.json",
  "deckAnchorHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.2,
        "x": 0.75,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Serum NfL concentration in pre-symptomatic CSF1R carriers vs controls",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5dc1bb9-2d44-4223-aac8-2f9d3b52cd33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.2,
        "x": 0.52,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Serum NfL concentration vs Age in symptomatic ALSP patients vs controls",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6ee989a-ca04-46b1-9d29-45a743305661",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "image",
      "text": "MRI scans showing progression of white matter lesions over 6 months",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b863f32-6de2-4cda-a53e-9607bf13e992",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.15,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Qualifiable white matter lesions, central atrophy and corpus callosum thinning. NfL (neurofilament light protein) biomarkers quantitatively associated with disease progression (~14x increase in serum and >30x increase in CSF) and present in pre-symptomatic carriers",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "062b7e65-f29d-4849-be88-bb4c9223bc67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "Oyanagi et al, Brain Pathol. 2017; Lakshmanan et al, Neurol Genet, 2017. Hayer et al, Neurology 2018. Kang et al. Radiol Case Rpts 2019; Huang et al. BMC Neurology 2021.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ceaf29bf-8e7e-46ee-8b6a-1ae390fdf029",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ALSP Has Both Distinct Pathology and Disease Biomarkers That Can Be Used in Clinical Development",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92429db4-3b90-4eeb-909a-95a7d6d9b66e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "b1c6a3a9-f230-4405-b8c8-3ec0ff6e111a",
      "evidence": "Serum NfL concentration vs Age in symptomatic ALSP patients vs controls",
      "confidence": 0.7
    },
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "3c11f09d-eb1f-4177-b568-58a298a195ae",
      "evidence": "Qualifiable white matter lesions, central atrophy and corpus callosum thinning",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 23,
      "beatId": "e3eb75f6-e675-4e37-8bf9-f4d5dbfb68fe",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents a clear problem statement and an explanation of the unmet medical need in neurodegenerative diseases.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 23,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e2005ee6-5f9f-4463-b0ef-3ff73d5299ad",
      "evidence": "The document presents the unmet medical need in ALSP and the potential benefits of treating it.",
      "position": 0,
      "objective": "What is the cost of not treating ALSP?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}